Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).

Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji RM, Casper J, Edinger M, Zák P, Yakoub-Agha I, Ciceri F, Schroeder T, Zuckerman T, Kobbe G, Yeshurun M, Narni F, Finke J, Diez-Martin JL, Berceanu A, Hilgendorf I, Verbeek M, Olivieri A, Savani B, Spyridonidis A, Nagler A, Mohty M

Open source

DOI: 10.1038/s41409-023-02028-x
Published: 2023 Oct
Container: Bone marrow transplantation
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41409-023-02028-x,
  title = {Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).},
  author = {Gavriilaki E and Sakellari I and Labopin M and Bornhäuser M and Hamladji RM and Casper J and Edinger M and Zák P and Yakoub-Agha I and Ciceri F and Schroeder T and Zuckerman T and Kobbe G and Yeshurun M and Narni F and Finke J and Diez-Martin JL and Berceanu A and Hilgendorf I and Verbeek M and Olivieri A and Savani B and Spyridonidis A and Nagler A and Mohty M},
  year = {2023},
  journal = {Bone marrow transplantation},
  doi = {10.1038/s41409-023-02028-x},
  url = {https://doi.org/10.1038/s41409-023-02028-x}
}

RIS

TY  - JOUR
TI  - Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).
AU  - Gavriilaki E
AU  - Sakellari I
AU  - Labopin M
AU  - Bornhäuser M
AU  - Hamladji RM
AU  - Casper J
AU  - Edinger M
AU  - Zák P
AU  - Yakoub-Agha I
AU  - Ciceri F
AU  - Schroeder T
AU  - Zuckerman T
AU  - Kobbe G
AU  - Yeshurun M
AU  - Narni F
AU  - Finke J
AU  - Diez-Martin JL
AU  - Berceanu A
AU  - Hilgendorf I
AU  - Verbeek M
AU  - Olivieri A
AU  - Savani B
AU  - Spyridonidis A
AU  - Nagler A
AU  - Mohty M
PY  - 2023
JO  - Bone marrow transplantation
DO  - 10.1038/s41409-023-02028-x
UR  - https://doi.org/10.1038/s41409-023-02028-x
ER  -

APA

E, G., I, S., M, L., M, B., RM, H., J, C., M, E., P, Z., I, Y., F, C., T, S., T, Z., G, K., M, Y., F, N., J, F., JL, D., A, B., I, H., M, V., A, O., B, S., A, S., A, N., & M, M. (2023). Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).. Bone marrow transplantation. https://doi.org/10.1038/s41409-023-02028-x

Source records

pubmed · retrieved 2026-09-27T12:00:10.748Z